SMStuart J. McCarter

Stuart J. McCarter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stuart J. McCarter has a total of 248 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pain in Isolated REM Sleep Behavior Disorder: Findings from Longitudinal and Deep-Phenotyping Cohorts

    by Lee E. Neilson, Jessica R. Locke, Nadir M. Balba, Matthew P. Butler, Scott D. Mist, Mary M. Heinricher, Don Bliwise, Meghan C. Campbell, Susan R. Criswell, Albert A. Davis, et al.

  • “Railroad Track” Brain Fluorodeoxyglucose-PET Sign in Antiphospholipid Syndrome–Related Posterior Cortical Atrophy

    by Yahel Segal, Allen J. Aksamit, Stuart J. McCarter, Stephanie B. Syc-Mazurek, John J. Chen, Gregory D. Cascino, Floranne C. Ernste, Samantha A. Banks

  • The Prodromal Synucleinopathy Rating Scale

    by Bradley F. Boeve, Yuzheng Nie, Ruijin Lu, Hernis De La Cruz, Alon Y. Avidan, Donald L. Bliwise, Meghan C. Campbell, Susan R. Criswell, Albert A. Davis, Kevin Duff, et al.

    Background and ObjectivesClinical trials in REM sleep behavior disorder (RBD) to delay or prevent the development of Parkinson disease (PD), dementia with Lewy bodies (DLBs), and multiple system at...


  • Open Access

    Clinical and Pathological Features of CSF1R-Related Disorder Associated With the p.R777Q Pathogenic Variant

    by Tomasz Chmiela, Delaney Liskey, Audrey J. Strongosky, Stuart J. McCarter, Paula Sandroni, Dennis W. Dickson, Zbigniew K. Wszolek

    Objective Colony-stimulating factor-1 receptor (CSF1R)-related disorder (CSF1R-RD) is a rapidly progressive neurodegenerative disease with a median onset of 43 years. More than 200 CSF1R pathogenic variants have been identified. Patients develop rapidly progressive dementia and motor symptoms, with a median disease duration of 6.8 years. The p.R777Q variant causes CSF1R-RD; it is deleterious to protein function. We describe the clinical and pathological features of CSF1R-RD associated with p.R777Q and report a new family carrying this variant. We compare the neuropathological findings of an index patient (with short-duration disease) with those of a patient with long-duration CSF1R-RD.Methods We present clinical and imaging data from a new family with p.R777Q. We also describe the neuropathology of an index patient and contrast these findings with features of a patient with CSF1R-RD with an 11-year disease course caused by the c.2656_2657insC variant.Results We reviewed the literature on 13 individuals from 8 families with the p.R777Q variant from Asia, Europe, and North America. The mean age at onset was 41±14 years, ranging from 22 to 63 years, and the mean survival was 3.3±2.5 years. Neuropathologic studies of our index patient (10-month disease duration) revealed features consistent with CSF1R-RD. Axonal and myelin pathology was severe in the periventricular white matter. Compared with the patient with an 11-year disease duration, the index patient had less severe white matter lesions.Conclusion Compared with CSF1R-RD associated with other variants, the p.R777Q variant has an aggressive course. Compared with the patient with a long disease duration, the index patient had milder neuropathological findings. These differences may be specific to p.R777Q or associated with rapid clinical progression.


  • Skin Biopsy for Phosphorylated α‐Synuclein in Mild Cognitive Impairment or Dementia Due to Lewy Body Disease in a Convenience Cohort from a Subspecialty Behavioral Neurology Practice

    by Michael J. Rigby, Hugo Botha, Leland R. Barnard, R. Ross Reichard, Rachel Larsen, Wendy Cogan, Aaron R. Switzer, Vijay K. Ramanan, Bryan J. Neth, Ryan A. Townley, et al.

    Background: Immunohistochemically detected phosphorylated α‐synuclein (p‐α‐syn) in cutaneous nerves has been found in >95% of patients meeting consensus criteria for dementia with Lewy bodies (DLB); however, its performance in prodromal stages (mild cognitive impairment‐Lewy body [MCI‐LB]) and clinical practice is unknown. Objective: We evaluated skin biopsy for p‐α‐syn in a convenience cohort of patients with suspected MCI‐LB or DLB in a tertiary care setting. Methods: 53 patients underwent commercially available skin biopsy for skin nerve p‐α‐syn as part of a clinical evaluation for suspected MCI‐LB/DLB. Consensus MCI‐LB/DLB criteria blinded to skin biopsy result were applied through retrospective chart review; those not definitively meeting criteria were considered questionable synucleinopathy (QS). Results: Median age at skin biopsy was 70 years (range, 43–87 years) with 81% men. 36 patients (68%) had positive skin biopsies. 32/43 (74%) patients meeting clinical consensus criteria for DLB/MCI‐LB had a positive skin biopsy, with higher frequency in MCI‐LB (87%) compared with DLB (60%). 4/10 (40%) QS had positive biopsies. One patient with a positive skin biopsy had no evidence of central nervous system (CNS) α‐syn on autopsy. Conclusions: Positive skin biopsy for p‐α‐syn occurs across the spectrum of cognitive presentations of Lewy body disease including prodromal DLB, albeit at a lower frequency in this retrospective review of atypical cases compared with typical clinical presentations. A positive skin biopsy may not reflect CNS synucleinopathy as the etiology for a patient's symptoms in some cases. Longitudinal studies of skin biopsies for p‐α‐syn in suspected MCI‐LB/DLB with autopsy confirmation are needed. © 2025 International Parkinson and Movement Disorder Society.


  • 123 I-FP-CIT SPECT in Autopsy-Proven Lewy Body Disease

    by Toji Miyagawa, Scott A. Przybelski, Cynthia J. Vernon, Hoon-Ki Paul Min, Leah Kathleen Forsberg, Julie A. Fields, Stuart J. McCarter, Tanis J. Ferman, Vijay K. Ramanan, Jonathan Graff-Radford, et al.


  • Core Clinical Features Associated With Survival in Patients With Dementia With Lewy Bodies

    by Stuart J. McCarter, Tanis J. Ferman, Kiera M. Grant, Jeremiah Aakre, David S. Knopman, Neill R. Graff-Radford, Leah K. Forsberg, Julie A. Fields, Gregory S. Day, Toji Miyagawa, et al.

    This analysis used clinical data from prospectively followed participants meeting criteria for probable dementia with Lewy bodies (DLB) in the Mayo Clinic Alzheimer's Disease Research Center (ADRC) between 1998 and 2024. DLB is characterized by unique core features of visual hallucinations (VHs), parkinsonism, REM sleep behavior disorder, and cognitive fluctuations with a variable disease course. DLB is associated with a poor prognosis, but whether these unique DLB core clinical features influence survival is unknown. We aimed to determine whether core clinical features are associated with survival in patients with probable DLB. Patients followed in the Mayo Clinic ADRC between 1998 and 2024 underwent annual clinical assessments. Those who met clinical criteria for probable DLB were analyzed. Time-dependent Cox proportional hazard models using age as the time scale determined associations between the individual and cumulative number of core clinical DLB features and survival. The prognostic significance of core features present at the time DLB criteria were met was assessed in separate models. Models were adjusted for sex and duration from the onset of cognitive symptoms to DLB diagnosis. Of 488 patients with probable DLB meeting inclusion criteria, 118 (24%) were women with a mean age of 71.9 ± 8.4 years at the time of meeting probable DLB criteria. Shorter survival was associated with the development of VHs (hazard ratio [HR] 3.25, 95% CI 2.46-4.29) and parkinsonism (HR 2.28, 95% CI 1.54-3.39) during the disease course and VHs at the time of DLB diagnosis (HR 1.60, 95% CI 1.18-2.16). All four core features were also associated with shorter survival (4 core features vs 2 core features, HR 3.58 95% CI 2.66-4.80, 4 core features vs 3 core features, HR 2.46, 95% CI 1.86-3.25). In 191 patients (45 women (24%) with a mean age of 71.2 ± 8.6 years at probable DLB diagnosis) with autopsy-confirmed DLB, VHs, parkinsonism, and all four core features were associated with shorter survival. Sex was not associated with survival. VHs, parkinsonism, and the development of all 4 core features were associated with shorter survival in probable and in autopsy-confirmed DLB. These findings have important prognostic and management implications for patients with DLB and their caregivers.


  • Top Cited Papers

    Associations of Chronic Insomnia, Longitudinal Cognitive Outcomes, Amyloid-PET, and White Matter Changes in Cognitively Normal Older Adults

    by Diego Z. Carvalho, Bhanu Prakash Kolla, Stuart J. McCarter, Erik K. St. Louis, Mary M. Machulda, Scott A. Przybelski, Angela J. Fought, Val J. Lowe, Virend K. Somers, Bradley F. Boeve, et al.

    The relationship between insomnia and cognitive decline is poorly understood. We investigated associations between chronic insomnia, longitudinal cognitive outcomes, and brain health in older adults. From the population-based Mayo Clinic Study of Aging, we identified cognitively unimpaired older adults with or without a diagnosis of chronic insomnia who underwent annual neuropsychological assessments (z-scored global cognitive scores and cognitive status) and had quantified serial imaging outcomes (amyloid-PET burden [centiloid] and white matter hyperintensities from MRI [WMH, % of intracranial volume]). We used mixed-effects models to examine associations between baseline insomnia (independently or with interaction with self-reported changes in habitual sleep duration) and longitudinal cognitive z-scores, log-transformed WMH, and amyloid-PET levels while adjusting for multiple confounders, including sleep apnea diagnosis. The risk of incident cognitive impairment (CI) was estimated using the Cox proportional hazards model. We included 2,750 participants (mean 70.3 ± 9.7 years old, 49.2% female) in global cognition models and 2,814 in Cox models with median follow-up of 5.6 years. A total of 1,027 and 561 participants were included in WMH and amyloid-PET models, respectively. Insomnia was associated with a 0.011 per year (95% CI -0.020 to -0.001, p-interaction = 0.028) faster decline in global cognitive scores and 40% increased risk of CI (hazard ratio [HR] 1.4, 95% CI 1.07-1.85, p = 0.015). Insomnia with reduced sleep was associated with baseline cognitive performance (β = -0.211, 95% CI -0.376 to -0.046, p-interaction = 0.012), WMH (β = 0.147, 95% CI 0.044-0.249, p-interaction = 0.005), and amyloid-PET (β = 10.5, 95% CI 0.5-20.6, p-interaction = 0.039) burden. Insomnia participants sleeping more than usual (potentially indicating remission of symptoms) had lower baseline WMH burden (β = -0.142, 95% CI -0.268 to -0.016, p-interaction = 0.028). Insomnia was not associated with the rate of WMH or amyloid accumulation over time. In participants with insomnia, hypnotic use was not associated with cognitive scores (β = 0.016, 95% CI -0.201 to 0.233, p = 0.888) or incident CI (HR 0.94, 95% CI 0.5-1.6, p = 0.832). We found an association between insomnia, cognitive decline, and increased risk for CI. Insomnia with reduced sleep was associated with worse cognitive performance and poorer brain health (WMH and amyloid burden) at baseline. Sleeping more than usual was associated with lower WMH burden.


  • Open Access

    Longitudinal Evolution of Posterior Cortical Atrophy

    by Dror Shir, Noah Lee, Stuart J. McCarter, Vijay K. Ramanan, Hugo Botha, David S. Knopman, Ronald C. Petersen, Bradley F. Boeve, Gregory Scott Day, Neill R. Graff-Radford, et al.

    Although several large studies have evaluated individuals with posterior cortical atrophy (PCA) cross-sectionally, its longitudinal progression remains poorly characterized. The objectives of this study were to determine the longitudinal trajectory of PCA, encompassing the temporal aspects of diagnosis, the spectrum of clinical manifestations, and patient outcomes. This retrospective study included participants evaluated and diagnosed with PCA at the Mayo Clinic, between 1995 and 2023. Clinical data (demographics, neurologic evaluations, and cognitive tests at initial presentation and late stage) were extracted from medical records. Initial clinical diagnoses during previous medical evaluations, including ophthalmologic assessments after onset of neurologic symptoms, were documented. Participants were retrospectively classified as PCA-pure if they solely met PCA criteria or as PCA-plus if they exhibited complex phenotypes also meeting criteria for other neurodegenerative syndromes. CSF analyses and neuropathology findings were documented. The cohort of 558 participants (65% female) had a mean age at symptom onset of 61 ± 8 years, with 68% meeting early-onset criteria (younger than 65 years). The mean duration from symptom onset to diagnosis was 3.6 ± 2.5 years. Ophthalmologic/optometric evaluations (49%) and completion of ophthalmologic procedures (16%) were common before PCA diagnosis. Psychiatric diagnoses were made in 23% of participants before PCA diagnosis, particularly among younger women. Common initial symptoms included misplacement of items, difficulties with reading and driving, and concerns pertaining to basic visual processing. Notable signs were constructional apraxia, dyscalculia, simultanagnosia, and space perception deficits. CSF biomarkers were consistent with Alzheimer disease in 139 of 158 individuals (88%). Superimposed features of non-PCA clinical syndromes were observed in a quarter of the participants at presentation, with frequency of PCA-plus cases increasing longitudinally. Longitudinal analysis of Short Test of Mental Status scores predicted an initial rapid decline in cognitive function, with the rate of decline gradually slowing over 0-10 years (time coefficient [SE] = -4.20 [0.29], p < 0.001). This study highlights the protracted time from symptom onset and frequent misdiagnoses/misattribution of symptoms in PCA. Ophthalmologic evaluations often preceded neurologic assessments. Psychiatric diagnoses were more frequent among younger women. These observations highlight the need to improve diagnostic processes and earlier recognition of PCA, which may enhance the effectiveness of emerging disease-modifying therapies.


  • Sleep and Prodromal Synucleinopathies

    by Johnson D. Pounders, Stuart J. McCarter

    α-synucleinopathies are a complex group of progressive neurodegenerative disorders with an increasingly recognized long prodromal period, during which sleep dysfunction is a hallmark. Sleep disorders during the prodromal synucleinopathy period, primarily isolated rapid eye movement (REM) sleep behavior disorder (iRBD) and daytime hypersomnolence correlate best with the recently proposed “body-first” Lewy body disease progression. iRBD is the most widely recognized form of prodromal α-synucleinopathy, and patients with iRBD show abnormal α-synuclein in tissues and biofluids even in the absence of cognitive or motor symptoms. More importantly, individuals with iRBD have an elevated risk for near-term development of a clinically diagnosable symptomatic synucleinopathy. Other sleep disorders such as hypersomnia and circadian rhythm dysfunction also occur across the synucleinopathy spectrum, although their prognostic significance is less well understood than iRBD. Finally, isolated REM sleep without atonia may represent an even earlier stage of prodromal synucleinopathy, but further studies are needed.